OOIR: Observatory of International Research

Papers

(The median citation count of Melanoma Research is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Genetic concordance in melanoma: insights from primary tumors and their matched distant metastases	24
Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel	17
Clinicopathological demographics of malignant melanomas of the vulva and vagina in Japan	17
Clinical features, molecular characteristics and surgical management of primary penile mucosal melanoma based on the European Association of Urology Penile Cancer Guidelines	17
Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?	16
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting	16
Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread	15
Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors	14
Immune-related adverse events are associated with therapeutic efficacy of immunotherapy in patients with melanoma brain metastases	13
Do cortisol and psychological distress levels impact the effectiveness of immunotherapy in patients with metastasized melanoma? A pilot study	13
Brain metastases during follow-up of patients with resected cutaneous melanoma	12
Study of clinical characteristics and risk factors for amelanotic/hypomelanotic melanoma in an Australian cohort	11
The potential of using artificial intelligence to improve skin cancer diagnoses in Hawai‘i’s multiethnic population	11
Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy	10
Comprehensive clinical imaging, histopathological analysis and liquid biopsy-based surveillance of human uveal melanoma in a prolonged rabbit xenograft model	10
Diffuse large B-cell lymphoma mimicking metastatic melanoma: the importance of biopsies in the era of immune checkpoint inhibitors	9
Cytomegalovirus gastritis as a rare adverse event during combined ipilimumab and nivolumab in a patient with melanoma	9
Assessment of lipid and pigment content in suspicious melanocytic lesions to improve melanoma detection	9
Association of baseline neutrophil-to-lymphocyte ratio and prognosis in melanoma patients treated with PD-1/PD-L1 blockade: a systematic review and meta-analysis	9
Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma	9
Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis: Erratum	9
Immunotherapy-induced granulomatous reaction in patients with melanoma	9
Ultraviolet A radiation exposure and melanoma: a review	9
GLI-1 polymorphisms of Hedgehog pathway as novel risk and prognostic biomarkers in melanoma patients	8
Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma	8

Pretreatment CD8+PD-1+ to CD4+PD-1+ ratio is associated with the prognosis of advanced melanoma patients treated with PD-1 inhibitors	8
Immunotherapy for treatment of female genital tract melanoma: National Cancer Database analysis	8
Regular use of vitamin D supplement is associated with fewer melanoma cases compared to non-use: a cross-sectional study in 498 adult subjects at risk of skin cancers	8
Diagnostic and prognostic value of Beclin 1 expression in melanoma: a meta-analysis	8
Challenging pigmented lesions in melanoma patients during checkpoint-inhibitors therapy	8
Uncomplicated pregnancy and delivery under ongoing nivolumab therapy for metastatic melanoma	8
LINC01063 functions as an oncogene in melanoma through regulation of miR-5194-mediated SOX12 expression	8
Clinical and dermoscopical presentation of nivolumab-induced pemphigoid in a metastatic melanoma patient	8
Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy	8
The effect of microRNA-9 overexpression on inhibition of melanoma cancer stem cells tumorigenicity	7
Neurologic adverse events associated with BRAF and MEK inhibitor therapy in patients with malignant melanoma: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporti	7
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series	7
Interfering with aggregated α-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins	7
Temporal correlation between the first melanoma and the first noncutaneous tumor in CKDN2A genotyped patients	7
Clostridium difficile infection and immune checkpoint inhibitor–induced colitis in melanoma: 18 cases and a review of the literature	7
Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases	7
Hemophagocytic lymphohistiocytosis induced by dabrafenib-trametinib in a patient with metastatic melanoma: a case report and pharmacovigilance analysis	7
Exacerbation of Kaposi sarcoma following BRAF/MEK inhibitor therapy in a melanoma patient: a case report and mechanistic insight	7
Successful encorafenib desensitization in a patient with recurrent metastatic melanoma	7
Documenting the histologic response of metastatic melanoma to combination therapy with BRAF and MEK inhibitors	7
Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment	6
Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition	6
Variance from published guidelines and changes in temporal trends in the management of cutaneous malignant melanoma: a 5-year update	6
Efficacy and safety of angiogenesis inhibitors in melanoma: a meta-analysis of seven randomized controlled trials	6
Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies	6
Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma	6
Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis	6
Proteomic profiles of melanoma cell-derived exosomes in plasma: discovery of potential biomarkers of melanoma progression	6
Temozolomide monotherapy versus combination therapies in melanoma: a meta-analysis of efficacy and safety	5
Simultaneous melanomas in the setting of multiple primary melanomas	5
Melanoma in the head and neck region: the value of preoperative imaging in melanoma stage I–II	5
Resolution of diffuse cuticular melanosis under immunotherapy in a patient with metastatic melanoma	5
Impact of systemic imaging surveillance on survival from metastatic uveal melanoma	5
Melanoma risk during immunomodulating treatment	5
Knockdown of enhancer of rudimentary homolog expression attenuates proliferation, cell cycle and apoptosis of melanoma cells	5
Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients	5
Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors	5
Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma	5
Identification of heterogeneity and prognostic key genes associated with uveal melanoma using single-cell RNA-sequencing technology	4
Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients	4
A retrospective study of clinicopathological and prognostic characteristics in 177 Chinese patients with acral melanoma: heterogeneity based on tumor site	4
Leptomeningeal dissemination as a first sign of progression in metastatic melanoma: a diagnostic lesson	4
Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis	4
The immunologic balance: three cases of rituximab-associated melanoma	4
Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma	4
COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: a case report	4
Molecular profiling of primary uveal melanoma: results of a Polish cohort	4
Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma	4
Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis	4
Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma	4

Successful use of rituximab for refractory hemophagocytic lymphohistiocytosis in a melanoma patient treated with targeted therapy	4
DNA methylation of GITR, OX40, 4-1BB, CD27, and CD40 correlates with BAP1 aberrancy and prognosis in uveal melanoma	4
The human and animals’ malignant melanoma: comparative tumor models and the role of microbiome in dogs and humans	4
Seborrheic keratosis-like melanoma: a diagnostic challenge	4
Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma	4
Management of heterogeneous tumor response patterns to immunotherapy in patients with metastatic melanoma	4
Reflectance confocal microscopy versus dermoscopy for the diagnosis of cutaneous melanoma: a head-to-head comparative meta-analysis	4
Combined PDE4+MEK inhibition shows antiproliferative effects in NRAS Q61 mutated melanoma preclinical models	4
Updates on the diagnosis, current and future therapeutic options in Merkel-cell carcinoma	4
Acute appendicitis secondary to desmoplastic melanoma metastasis in immune-checkpoint inhibitors era	4
Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors	3
Ultra-high-frequency ultrasound monitoring of melanomas arising in congenital melanocytic nevi: a case series	3
Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs: results of 60 patients treated in Finland during 2007–2018	3
ATF3 regulates CDC42 transcription and influences cytoskeleton remodeling, thus inhibiting the proliferation, migration and invasion of malignant skin melanoma cells	3
Efficacy of local ablative therapies in patients with solid tumors treated with immune checkpoint inhibitors and oligoprogression: a single-center analysis	3
Direct early growth response-1 knockdown decreases melanoma viability independent of mitogen-activated extracellular signal-related kinase inhibition	3
Retrospective comparison of a weight-based dose every 2 weeks with a fixed dose every month: a real-life analysis of nivolumab in the treatment of advanced melanoma	3
Lower melanoma pulmonary metastatic burden in obese mice: role of FGF-21	3
First-time office visit for suspicious skin lesion evaluation as a predictor of high-risk melanoma	3
Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: a noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early acce	3
High-resolution RNA-sequencing reveals TRIM33::CSDE1 gene fusion in metastasizing vulvar melanoma	3
Noncontrast-enhanced 3-Tesla MRI using surface coil as a complementary test for assessment of distribution and depth of locoregional cutaneous metastases of malignant melanoma	3
Exploring the role of epigenetic alterations and non-coding RNAs in melanoma pathogenesis and therapeutic strategies	3
Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice	3
Neonatal cutaneous melanoma with cutaneous metastasis: a case report and review of literature	3
A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors	3
Correlations between inflammatory cytokine levels and degree of pigmentation in acral melanomas	3
Psychosocial wellbeing in people with melanoma in-situ: a systematic review	3
Uveal melanoma metastatic at initial diagnosis: a case series	3
Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL)	3
Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma	2
Talimogene laherparepvec monotherapy for head and neck melanoma patients	2
Pregnancy-associated melanoma: characteristics and outcomes from 2002 to 2020	2
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors	2
Influence of regression, its extent and tumor-infiltrating lymphocytes on sentinel node status, relapse, and survival in a 10-year retrospective study of melanoma patients	2
The death rate for melanoma remained unchanged in the USA during the coronavirus disease 2019 pandemic	2
Vitiligo-like hypopigmentation secondary to adjuvant checkpoint inhibitor therapy in patients with resectable stage III melanoma: a cohort from two tertiary hospitals	2
Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma	2
Clinical features of vulvar and vaginal malignant melanomas and the effects of immune checkpoint inhibitors in Japanese patients: a single-center, retrospective cohort study	2
Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging	2
The importance of mitosis ≥2 in selecting patients with T1 cutaneous melanomas for sentinel lymph node biopsy	2
Survivals following discontinuation of PD-1 inhibitor treatment in advanced melanoma patients	2
Description of supportive care and feasibility of physical exercise program to improve quality of life in advanced melanoma patients	2
Cardiovascular disease and malignant melanoma	2
Underreporting of acral lentiginous melanoma in studies informing American Joint Committee on Cancer Staging System Guidelines: a review of 150 cited studies	2
Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis	2
Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma	2
pSTAT5 is associated with improved survival in patients with thick or ulcerated primary cutaneous melanoma	2
Relation between dabrafenib plus trametinib-induced pyrexia and age in BRAF V600-mutated metastatic melanoma patients: A post hoc analysis of the real-world ELDERLYMEL study	2
Retrospective analysis of adjuvant therapy using dabrafenib plus trametinib in Japanese patients with advanced melanoma: analysis of 36 cases	2
Impact of gene expression profiling on diagnosis and survival after metastasis in patients with uveal melanoma	2
Diagnosis and management of concurrent metastatic melanoma and chronic myelomonocytic leukemia	2
Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma	2
A case of hyperprolactinaemia in a patient with metastatic melanoma	2
Polymorphisms in toll-like receptor 3 and 4 genes as prognostic and outcome biomarkers in melanoma patients	2
Anorectal melanoma: systematic review of the current literature of an aggressive type of melanoma	2
Safety of immune checkpoint inhibitors after proton beam therapy in head and neck mucosal melanoma: a case series	2
Prognostic significance of tumor budding in melanoma	2
Clinical performance indicators for monitoring the management of cutaneous melanoma: a population-based perspective	2
The role of artificial intelligence and convolutional neural networks in the management of melanoma: a clinical, pathological, and radiological perspective	2
LS-007 inhibits melanoma growth via inducing apoptosis and cell cycle arrest and regulating macrophage polarization	2
Immunohistochemistry assessment of tissue neutrophil-to-lymphocyte ratio predicts outcomes in melanoma patients treated with anti-programmed cell death 1 therapy	2
Female melanoma and estrogen receptors expression: an immunohistochemical pilot study	2
Pembrolizumab-induced hypothyroidism manifesting as myopathy and psychosis	2
BRCA1-associated protein 1 c.368delG mutation leads to the development of multiple BAPomas and cutaneous melanomas: a novel pathogenic variant in BRCA1-associated protein tumor predisposition syndrome	2
Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results	2
The effect of COVID-19 on early melanoma detection	2
Expect the unexpected: a saying to bear in mind	2
Rate of response to immune checkpoint inhibitor therapy in patients with conjunctival melanoma	2
Eruptive melanocytic nevi in a patient with amelanotic melanoma: a paraneoplastic phenomenon?	2
Open-label nonrandomized phase IB study to characterize the safety and recommended dose of tinostamustine in combination with nivolumab in patients with advanced melanoma (ENIgMA)	2
Expression of cathepsins B and D by cancer stem cells in head and neck metastatic malignant melanoma	2
Preoperative assessment of cutaneous melanoma thickness by multispectral dermoscopy	2
Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure	2